Welcome to our dedicated page for Alpha Tau Medical news (Ticker: DRTS), a resource for investors and traders seeking the latest updates and insights on Alpha Tau Medical stock.
Alpha Tau Medical Ltd. develops Alpha DaRT, an intratumoral alpha-radiation therapy being studied for solid tumors. News about DRTS centers on clinical development, regulatory interactions and scientific presentations for Alpha DaRT across oncology programs including recurrent cutaneous squamous cell carcinoma, pancreatic cancer, recurrent glioblastoma, and head and neck cancer.
Company updates frequently cover trial data, feasibility and safety findings, patient enrollment milestones, FDA device-pathway activity, conference abstracts and global study expansion. The news also reflects the company's focus on localized alpha-emitter radiation intended to treat tumors while limiting exposure to surrounding tissue.
On June 7, 2022, Alpha Tau Medical Ltd. (Nasdaq: DRTS) announced the resignation of board member Gary Leibler, effective immediately. His departure is cited as unrelated to the company’s performance. CEO Uzi Sofer expressed gratitude for Leibler’s significant contributions since the company's inception. Despite his resignation, Leibler remains optimistic about Alpha Tau’s prospects, especially following its successful NASDAQ public listing, which provided essential capital for advancing its innovative Alpha DaRT cancer treatment technology.
Alpha Tau Medical Ltd. (NASDAQ: DRTS) reported its first quarter 2022 financial results and updated on corporate milestones. The company raised approximately $104 million through its public debut in March 2022 and plans to initiate a pivotal U.S. trial for skin cancers mid-2022. Key highlights include a complete response rate of 100% in a pilot study for malignant skin cancer and significant advancements in manufacturing and supply chain capabilities. However, the company reported a net loss of $25.7 million, or ($0.54) per share, and expects its cash balance of $107 million to sustain operations for two years.
Alpha Tau Medical (Nasdaq: DRTS) has commenced treatment of its first patients in a French multicenter trial utilizing its innovative alpha-radiation therapy, Alpha DaRT™, for skin cancer. The trial, led by Dr. Pascal Pommier at the Leon Berard Center in Lyon, includes two cohorts focusing on newly diagnosed patients and those with recurrent disease. The main goal is to evaluate the overall response rate after treatment. CEO Uzi Sofer expressed excitement over the study, aiming to provide new treatment options for patients with limited alternatives.
On March 28, 2022, Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) reported its 2021 financial results, highlighting a significant 100% complete response rate in its U.S. pilot trial for skin cancer. The company received two FDA breakthrough device designations and successfully completed its merger with Healthcare Capital Corp, raising approximately $90 million. R&D expenses increased to $11.4 million, resulting in a net loss of $27.3 million for the year. As of December 31, 2021, Alpha Tau's cash reserves stood at $31.9 million, expected to sustain operations for two years.